Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISIONARY phase 3 trial of sibeprenlimab in IgA nephropathy
NL-OMON59730Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Sibeprenlimab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Relative change in urine protein-creatinine ratio at 9 months. Started Apr 2023; status: completed.
02
Drugs
sibeprenlimab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NL-OMON59730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59730.